12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

JVS-100: Phase I/II started

Juventas began the U.S. Phase I/II RETRO-HF trial to evaluate 30 or 45 mg JVS-100 delivered retrograde via the coronary sinus through the Oscor Venos Occlusion Balloon Catheter in about 72 patients with ischemic cardiomyopathy. The...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >